09.13.13
Phillips-Medisize Corporation, a contract manufacturing company based in Hudson, Wis., has inked a deal to purchase Adval Tech Holding AG’s assets in Mexico and China. The value of the deal has not been disclosed.
The Suzhou, China medical technology facility—Adval Tech Medical (Suzhou) Co. Ltd.—is both ISO 9001- and 13485- compliant and certified by China’s State Food and Drug Administration to manufacture finished drug delivery systems and related medical devices. The Queretaro, Mexico, facility (Omni Manufacturing Services S.A. de C. V.) also is ISO 9001 and 13485-compliant and U.S. Food and Drug Administration-registered to manufacture components and subassemblies, drug delivery systems and other related medical devices.
Phillips-Medisize plans to retain approximately all 350 employees from both operations, which executives hope will ensure continuity for all existing customers of the operations. This also is hoped to position Phillips-Medisize to begin serving its global customer base from these locations immediately.
“We are very pleased to welcome the China and Mexico employees to the Phillips-Medisize team,” said Matt Jennings, president and CEO of Phillips-Medisize. “This acquisition reflects continued successful execution of our strategic acquisition growth strategy to offer our customers a global manufacturing and designing standard while providing local production and development capabilities. Because these facilities are state-of-the-art manufacturing sites to Switzerland standards, in China and Mexico, we expect these operations will integrate rapidly and seamlessly into Phillips-Medisize and be available immediately to support our global customers.”
The Suzhou, China medical technology facility—Adval Tech Medical (Suzhou) Co. Ltd.—is both ISO 9001- and 13485- compliant and certified by China’s State Food and Drug Administration to manufacture finished drug delivery systems and related medical devices. The Queretaro, Mexico, facility (Omni Manufacturing Services S.A. de C. V.) also is ISO 9001 and 13485-compliant and U.S. Food and Drug Administration-registered to manufacture components and subassemblies, drug delivery systems and other related medical devices.
Phillips-Medisize plans to retain approximately all 350 employees from both operations, which executives hope will ensure continuity for all existing customers of the operations. This also is hoped to position Phillips-Medisize to begin serving its global customer base from these locations immediately.
“We are very pleased to welcome the China and Mexico employees to the Phillips-Medisize team,” said Matt Jennings, president and CEO of Phillips-Medisize. “This acquisition reflects continued successful execution of our strategic acquisition growth strategy to offer our customers a global manufacturing and designing standard while providing local production and development capabilities. Because these facilities are state-of-the-art manufacturing sites to Switzerland standards, in China and Mexico, we expect these operations will integrate rapidly and seamlessly into Phillips-Medisize and be available immediately to support our global customers.”